| The clinical utility of urine lipoarabinomannan and the novel point-of-care lateral flow strip test (Determine® TB) for the diagnosis of tuberculosis in hospitalised patients … JG Peter, A Haripesad, L Mottay, S Kraus, R Meldau, K Dheda C94. DETECTING AND PREVENTING TUBERCULOSIS AND DRUG-RESISTANT TUBERCULOSIS …, 2011 | 1351 | 2011 |
| The international WAO/EAACI guideline for the management of hereditary angioedema–the 2017 revision and update M Maurer, M Magerl, I Ansotegui, E Aygören-Pürsün, S Betschel, K Bork, ... World Allergy Organization Journal 11, 1-20, 2018 | 869* | 2018 |
| Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial G Theron, L Zijenah, D Chanda, P Clowes, A Rachow, M Lesosky, W Bara, ... The Lancet 383 (9915), 424-435, 2014 | 545 | 2014 |
| Antibiotic allergy KG Blumenthal, JG Peter, JA Trubiano, EJ Phillips The Lancet 393 (10167), 183-198, 2019 | 501 | 2019 |
| Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting G Theron, J Peter, R van Zyl-Smit, H Mishra, E Streicher, S Murray, ... American journal of respiratory and critical care medicine 184 (1), 132-140, 2011 | 401 | 2011 |
| Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic … JG Peter, LS Zijenah, D Chanda, P Clowes, M Lesosky, P Gina, N Mehta, ... The Lancet 387 (10024), 1187-1197, 2016 | 279 | 2016 |
| The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study GL Calligaro, U Lalla, G Audley, P Gina, MG Miller, M Mendelson, ... EClinicalMedicine 28, 2020 | 238 | 2020 |
| The global burden of chronic urticaria for the patient and society M Gonçalo, A Gimenéz‐Arnau, M Al‐Ahmad, M Ben‐Shoshan, ... British Journal of Dermatology 184 (2), 226-236, 2021 | 205 | 2021 |
| Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples K Dheda, V Davids, L Lenders, T Roberts, R Meldau, D Ling, L Brunet, ... PloS one 5 (3), e9848, 2010 | 192 | 2010 |
| Controversies in drug allergy: testing for delayed reactions EJ Phillips, P Bigliardi, AJ Bircher, A Broyles, YS Chang, WH Chung, ... Journal of Allergy and Clinical Immunology 143 (1), 66-73, 2019 | 188 | 2019 |
| Point‐of‐care diagnosis of tuberculosis: Past, present and future K Dheda, M Ruhwald, G Theron, J Peter, WC Yam Respirology 18 (2), 217-232, 2013 | 183 | 2013 |
| Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? G Theron, J Peter, D Dowdy, I Langley, SB Squire, K Dheda The Lancet infectious diseases 14 (6), 527-532, 2014 | 180 | 2014 |
| Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients JG Peter, G Theron, R van Zyl-Smit, A Haripersad, L Mottay, S Kraus, ... European respiratory journal 40 (5), 1211-1220, 2012 | 176 | 2012 |
| Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? G Theron, R Venter, G Calligaro, L Smith, J Limberis, R Meldau, ... Clinical Infectious Diseases 62 (8), 995-1001, 2016 | 164 | 2016 |
| Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments J Peter, C Green, M Hoelscher, P Mwaba, A Zumla, K Dheda Current opinion in pulmonary medicine 16 (3), 262-270, 2010 | 159 | 2010 |
| Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments G Theron, J Peter, G Calligaro, R Meldau, C Hanrahan, H Khalfey, ... Scientific reports 4 (1), 5658, 2014 | 150 | 2014 |
| The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second‐line anti‐tuberculosis drugs G Theron, J Peter, M Richardson, M Barnard, S Donegan, R Warren, ... Cochrane Database of Systematic Reviews, 2014 | 149 | 2014 |
| Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice JG Peter, R Lehloenya, S Dlamini, K Risma, KD White, KC Konvinse, ... The Journal of Allergy and Clinical Immunology: In Practice 5 (3), 547-563, 2017 | 141 | 2017 |
| Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid G Theron, J Peter, R Meldau, H Khalfey, P Gina, B Matinyena, L Lenders, ... Thorax 68 (11), 1043-1051, 2013 | 136 | 2013 |
| The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions K Dheda, T Perumal, H Moultrie, R Perumal, A Esmail, AJ Scott, ... The Lancet Respiratory Medicine 10 (6), 603-622, 2022 | 134 | 2022 |
Keertan DhedaProfessor, University of Cape Town & London School of Hygiene and Tropical MedicineVerified email at uct.ac.za
